Novo Nordisk(US:NVO) Globenewswire·2025-09-19 20:44Core Viewpoint - A class action securities lawsuit has been filed against Novo Nordisk A/S, alleging securities fraud that negatively impacted investors between May 7, 2025, and July 28, 2025 [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Novo Nordisk made misleading statements regarding its growth potential, particularly underestimating the impact of the personalization exception to the compounded GLP-1 exclusion and overstating the likelihood of patients switching to its branded alternatives [2]. - On July 29, 2025, Novo announced a reduction in its sales and profit outlook, attributing this to lower growth expectations for Wegovy and Ozempic due to competition and the persistent use of compounded GLP-1s [2]. - Following the announcement, Novo's stock price plummeted from $69.00 per share on July 28, 2025, to $53.94 per share on July 29, 2025, marking a decline of approximately 21.83% in one day [2]. Group 2: Legal Proceedings and Participation - Investors who suffered losses during the specified timeframe have until September 30, 2025, to request to be appointed as lead plaintiff in the lawsuit [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and participation does not require serving as a lead plaintiff [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].